
Victor S Lin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8823829/publications.pdf

Version: 2024-02-01



| # | Article | IF | CITATIONS |
|---|--|-----|-----------|
| 1 | BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax. Blood, 2020, 135, 2266-2270. | 1.4 | 67 |
| 2 | Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition. Blood Advances, 2021, 5, 4054-4058. | 5.2 | 39 |
| 3 | Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months. Blood Advances, 2020, 4, 165-173. | 5.2 | 34 |
| 4 | Clonal hematopoiesis, myeloid disorders and <i>BAX</i> -mutated myelopoiesis in patients receiving venetoclax for CLL. Blood, 2022, 139, 1198-1207. | 1.4 | 34 |
| 5 | BH3 Mimetics for the Treatment of B-Cell Malignancies—Insights and Lessons from the Clinic. Cancers, 2020, 12, 3353. | 3.7 | 12 |
| 6 | Venetoclax for the treatment of mantle cell lymphoma. Annals of Lymphoma, 2019, 3, 4-4. | 4.5 | 1 |